**Comparison of Zoledronic Acid Every 12 Weeks versus Standard 4 Weeks Regimen in Breast Cancer Patients with Bone Involvement**

Emad Sadaka1 and Rasha Khedr2

1Clinical Oncology Department, Faculty of Medicine, Kafer Elsheikh University, Egypt

2Clinical Oncology Department, Faculty of Medicine, Tanta University, Egypt

[e\_sadaka@hotmail.com](mailto:e_sadaka@hotmail.com)

**Abstract: Purpose:** The present study is to evaluate the 12 weeks interval of zoledronic acid compared to the 4 weeks regimen. **Methods**: Patients were distributed in 2 groups, for receive 4.0 mg of intravenouszoledrnic acid every four weeks (group 1) or 12 weeks (group 2) / year. One hundred and forty patients (140) were enrolled in this study on 69 patients randomly to receivezoledrnic acid every four weeks and 71patients randomly receivedzoledronic acid every 12 weeks. The primary endpoint was the proportion of patients having at least 1 SRE within 1 year after that. Secondary end points included pain, the incidences of adverse events of zoledrnic acid (osteonecrosis and renal dysfunction) and the skeletal morbidity rate. **Results***:* After 1 years of follow-up, SREs occurred in 15 (21.7%) patients in the zoledrnic acid every 4 weeks group and 16 (22.5%) patients in zoledrnic acid every 12 weeks group; (no inferiority with P= 0.910).The time to first SRE between treatment groups was not statistically significantly different (hazard ratio (HR, 1.04; 95% CI, 0.52-2.1; P = 0.903). According to pain score the 2 treatment groups was not statistic significant different (p=0.595). The mean skeletal morbidity rate (SMR) 0.46 (1.06) vs. 0.50 (1.50) events per year in the every four weeks versus every 12 weeks groups (P = .85). **Conclusion:** Zoledrnic acid every 12 weeks compared with every 4 weeks did not result in an increased risk of skeletal events seems to be noninferior and may be an acceptable treatment option.

EmadSadaka and RashaKhedr. **Comparison of Zoledronic Acid Every 12 Weeks versus Standard 4 Weeks Regimen in Breast Cancer Patients with Bone Involvement.** *Cancer Biology* 2018;8(3):38-41]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>.7. doi:[10.7537/marscbj080318.07](http://www.dx.doi.org/10.7537/marscbj080318.07).

**Keywords**:Zoledronic acid, skeletal events, adverse events.

**1. Introduction**

Metastatic breast cancer to bone is a common clinical problem. 1It hasmany debilitating skeletal-related events (SREs), that included the bone fractures, hypercalcemia, nerve compression, and severe pain2 These skeletal complications, in turn, increase the need for palliative radiation or surgery to bone3 limit functional independence, adversely affect the quality of life4,5 and continue to cause morbidity of the affected patients. 6,7

Zoledronic acid was approved for patients with metastases of bone from solid tumors. The use of zoledronic acid every three to four weeks decreases pain, compression of spinal cord, bone radiation and surgery by 25% to 40%.1,8,9

The bone-modified considered the guidelines of agents in metastatic breast-cancer which were verified by American society of clinical oncology (ASCO).10,11 These agents include BPs and new osteoclastinhibitors. These agents are recorded in bone metastases of breast cancer with bone loss. They advise to have a dental examination before bisphosphonate (BP) administration with follow upcreatinine levels. Agents include zoledronic acid (ZA), pamidronate (PA) and denosumab.

Amadori et al,12 studied patients with metastatic breast cancer to bone treated with zoledronic acid administered at 12-weeksversus 4-weeks. There was nosignificant difference as regard skeletal morbidity rate (0·26 in the 12, week group 0·22 (0·14–0·29) in 4, week group. Bone pain was recorded in (27%) of patients in the 12-week arm vs (30%) of the 4-week arm. There were no significant differences as regards to renal impairment, bony pains and osteonecrosis.

This study is to evaluate the 12 weeks interval of zoledronic acid compared to the 4 weeks regimen.

**2. Patients and Methods**

Pathologically proven breast cancer with at least 1 site of bone metastasis documented by plain radiograph required, CT scan, PET scan, MRI or bone scan. Age of 21 years or older, Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2, calculated creatinine clearance13, and serum calcium level within normal ranges (between8.0 to 11.6 mg/dL).


Patients were ineligible if they had received prior intravenous bisphosphonates, denosumab, or bone-targeting radiopharmaceuticals. Patients received priorirradiation to bone were excluded.

Patients were distributed in 2 groups,to receive 4.0 mg of intravenous zoledronic acid every 4 weeks (group 1) or every 12 weeks (group 2) for 1 year. This study was conducted at oncology department, Tanta university hospitals, Egypt the period from January 2014 up to June 2018. One hundred and forty patients (140) were enrolled in the study with 69 patients randomized to receive zoledronic acid every 4 weeks and 71patients randomized to receive zoledronic acid every 12 weeks.

Patients encouraged swallowing elemental calcium and vitamin D. The zoledronic acid adverse effects wereassessed according to Common Terminology Criteria for Adverse Events, version 3.14

The primary endpoint was the proportion of patients having at least 1 SRE within 1 year after randomization, it is defined as pathological fracture, spinal cord compression, palliative radiation to bone, and surgery involving affected bone to treat pathological fractures or spinal cord compression.

Secondary end points included pain as assessed by scores ranged from score 0 (no pain) to score 10 (as bad as you can imagine), mild pain (1-4), moderate pain (5-7) and sever pain (8-10)15, the incidences of adverse events of zoledronic acid (osteonecrosis and renal dysfunction) was assessed; (grade 1, serum creatinine levels 1.5 times greater than the upper limit of normal; grade 2, >1.5–3.0 times; grade 3, >3.0–6.0 times the upper limit of normal; grade 4, >6 times the upper limit of normal), and the skeletal morbidity rate was defined as the mean number of skeletal-related events per year. Skeletal related events were evaluated every 4 weeks for all patients. Also, imaging reports, pain scores, serum creatinine levels, creatinine clearance.

****

**Figure (1):** Kaplan Meier curve for time to first skeletal related event

**3. Results**

**Table (1) Patient's characteristics**

|  |  |  |
| --- | --- | --- |
|  | every 4 weeks (no=69) | every 12 weeks (no=71) |
| Age, median (range), y  Body surface area, mean (SD)   |  | | --- | | Performance status, No. (%) |   **0**  **1**  Serum creatinine, median (IQR) | 65 (26-93)  1.9 (0.3)  10 (14.49%)  59(85.6%)  0.9 (0.7-1.0) | 65 (33-94)  2.0 (0.3)  9 (12.68%)  62(87.32%)  0.9 (0.7-1.1) |

After 1 years of follow-up, SREs occurred in 15 (21.7%) patients in the zoledronic acid every 4 weeks group and 16 (22.5%) patients in the zoledronic acid every 12 weeks group; (noninferior with P= 0.910). Table 2

Table (2): Comparison between zoledronic acid every 4 weeks and Every 12 weeks according to SRE

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Zoledronic acid every 4 weeks**  **(n= 69)** | **Every 12 weeks**  **(n= 71)** | **p** |
| **SRE** |  |  |  |
| No | 54(78.3%) | 55(77.5%) | 0.910 |
| Yes | 15(21.7%) | 16(22.5%) |

The time to first SRE between treatment groups was not statistically significantly different (HR, 1.04; 95% CI, 0.52-2.1; P = 0.903). Table 3, Figure1.

**Table (3): Time to first skeletal related event**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Mean** | **95% CI of mean**  **(LL-UL)** | **%** | **Hazard ratios**  **(95% CI)** | |
| **p** |  | |
| **Every 4 weeks** | 20.913 | 19.473 – 22.353 | 78.3 | 0.903 | 1.04  (0.52 – 2.1) | |
| **Every 12 weeks** | 20.662 | 19.183 – 22.141 | 77.5 |

According to pain score the 2 treatment groups was not statistically significantly different (p=0.595). Table 4

**Table (4): Zoledronic acid every 4weeks and Every 12 weeks according to pain Score**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **4weeks group**  **(n= 69)** | **Every 12weeks**  **(n= 71)** | **p** |
| **Pain Score** |  |  |  |
| 0 | 2(2.9%) | 1(1.4%) | 0.959 |
| Mild | 21(30.4%) | 20(28.2%) |
| Moderate | 35(50.7%) | 38(53.5%) |
| Severe | 11(15.9%) | 12(16.9%) |

The mean skeletal morbidity rate (SMR) 0.46 (1.06) vs. 0.50 (1.50) events per year in the every 4 weeks versus every 12 weeks groups (P = .85)

The safety profiles of the every four weeks and every 12weeks groups were comparing, with only 2 patients (0.029%) in the every 4weeks group complained from renal dysfunction versus one patient (0.014) in the every 12 weeks group. No patients experienced osteonecrosis in both groups.

**4. Discussion**

This study included metastatic breast cancer to bone patients. The administered of zoledrnic acid every 12weeks was non inferior to that administered every 4weeks for reducing the occur in skeletal events, (21.7%) of patients every 4weeks versus (22.5%) in every 12weeks groups). The time between treated groups with SRE was of no statistical significantly different (hazard ratio [HR], 1.04; 95% CI, 0.52-2.1; P = 0.903). The mean skeletal morbidity rate (SMR) was noninferior, 0.48 (1.08) versus 0.51 (1.51) events per year in the every 4 weeks vs. every 12 weeks groups (P = 0.85).

Similar observations were made in OPTIMIZE-2 study17 44 patients (22.0%) in every four weeks group vs. 47patients (23.2%) in the every 12weeks group experienced 1 or more SRE and ZOOM study12 31 of 209 (15%) patients in the 12week group and 33 of 216 (15%) in the 4-week group (p=0·898). The SRE was not statistical significant was differ (HR, 1.6; 95% CI, 0.70-160; P = 0.79). The median time to first SRE could not be calculated in ZOOM study10 because of the low event rate. At same time, there was no statistically significant between treatment groups (P= 0.46vs. 0.50). Also SMR was not statistically significant in ZOOM study10 (95% CI) 0·26 (0·15–0·37) in 12 week group vs 0·22 (0·14–0·29) in 4 week group.

In present study, the incidence of renal impairment of the 2 treatment arms was comparable (only 2 patients (0.02.8) in the every four weeks versus one patient (0.014) in the every 12 weeks group).

In the ZOOM study10, Renal adverse occur in 1 patient (<1%) in the group, 12-week and two patients (1%) in the group, 4-week. One patient (<1%) in the fourweek group had non-serious acute grade 1 renal failure. According to pain score the 2 treatment groups was not statistically significantly different in this study  (p=0.595). The OPTIMIZE-2 study17 assessed bonepain by the Brief Pain Inventory (BPI) and analgesic consumption, pain score and analgesic consumption was not statistically different between groups (P =0.1) .

Ling et al 18reorted that there were no differences in the incidence of skeletal-related events (*P* = 0.80) or grade 3/4 adverse events (*P =* 0.52) were observed between the 12-week and 4-week schedule of zoledronic acid. The 12-weeks arm have lower incidences osteonecrosis in jaw (0.98%) versus (1.73%) and renal impairment (1.68%) versus (2.45%) withno significant difference (*P=* 0.11); (*P =* 0.15) respectively. They claimed that zoledronic acid at 12-weeks intervals don't increase risk of SREs, and maybe reduce the incidence of osteonecrosis of jaw and kidney failure.

**References**

* 1. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005; 23(15):3314–3321.
  2. Clément-Demange L, Clézardin P. Emerging therapies in bone metastasis. Curr Opin Pharmacol. 2015; 22:79-86.
  3. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8) (suppl):1588-1594.
  4. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004; 42(2): 164-175.
  5. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009;6(3):163-174.
  6. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867.
  7. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005; 23(22):4925-4935.
  8. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458–1468.
  9. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005; (3): CD003474.
  10. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29:1221–1227.
  11. Van Poznak CH, Von Roenn JH, Temin S. American Society of Clinical Oncology clinical practice guideline update: recommendations on the role of bonemodifying agents in metastatic breast cancer. J Oncol Pract 2011; 7:117–121.
  12. Amadori D1, Aglietta M, Alessi B, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013 Jun; 14(7):663-70.
  13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31–41.
  14. Cancer Therapy Evaluation Program. [Accessed December 6, 2016]; Common Terminology Criteria for Adverse Events, Version 3.0.
  15. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23(2):129–138.
  16. Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines (2014). Ann Oncol. 25(suppl 3): iii124-iii37.
  17. Hortobagyi GN1, Van Poznak C2, Harker WG3, et al. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jul 1; 3(7):906-912.
  18. Ling Cao, Yong-Jing Yang, Jian-Dong Diao, et al.: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. Oncotarget, 2017, Vol. 8, (No. 52), pp: 90308-90314.

8/14/2018